HBIO · XBRL financial data

Harvard Bioscience financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (HBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	102,100	118,904	113,335	112,250	94,135	86,550
Cost of goods and services sold	44,059	51,252	52,516	46,179	39,369	36,640
Gross profit	58,041	67,652	60,819	66,071	54,766	49,910
Research and development	8,685	10,799	12,329	11,764	10,406	8,825
General and administrative	23,509	24,305	24,493	22,780	21,493	17,742
Total operating expenses	57,820	65,586	67,752	64,177	60,977	98,490
Operating income (loss)	221	2,066	(6,933)	1,894	(6,211)	(48,580)
Interest expense	—	—	—	—	800	3,600
Other income (expense)	(806)	(666)	302	(227)	(652)	(2,656)
Income tax expense (benefit)	518	148	337	859	740	(686)
Net income (loss)	(7,810)	(288)	(9,516)	(3,415)	(12,405)	(56,700)
Earnings per share, basic USD per share	—	(0.01)	(0.23)	(0.08)	(0.28)	(1.28)
Earnings per share, diluted USD per share	—	—	(0.23)	(0.08)	(0.28)	(1.28)
Weighted average shares, basic thousands of shares	38,640	40,343	41,413	42,420	43,538	44,391
Weighted average shares, diluted thousands of shares	38,640	40,343	41,413	42,420	43,538	44,391

Fiscal years (HBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	8,317	7,821	4,508	4,283	4,108	8,614
Accounts receivable	17,766	21,834	16,705	16,099	14,866	16,043
Inventory	22,262	27,587	26,439	24,716	23,245	20,805
Total current assets	51,700	61,583	51,124	49,038	45,117	48,225
Property and equipment, net	3,960	3,415	3,366	3,981	5,106	4,787
Right-of-use asset	7,761	6,897	5,816	4,773	6,132	7,172
Goodwill	58,590	57,689	56,260	57,065	56,324	9,559
Total assets	156,254	162,344	145,360	137,366	126,644	80,071
Accounts payable	5,972	4,911	6,447	5,554	4,787	3,652
Current portion of long-term debt	2,000	3,515	4,091	6,139	37,350	0
Total current liabilities	21,053	25,316	23,249	26,542	54,958	21,960
Long-term debt	46,286	45,095	43,013	30,704	0	35,870
Lease liability, non-current	7,481	6,488	5,282	4,794	6,381	6,882
Total liabilities	79,573	78,943	73,140	64,292	63,304	66,337
Accumulated deficit	(132,386)	(132,674)	(142,190)	(145,605)	(158,010)	(214,710)
Total stockholders' equity	76,681	83,401	72,220	73,074	63,340	13,734
Total liabilities and equity	156,254	162,344	145,360	137,366	126,644	80,071
Common shares outstanding (cover page) thousands of shares	39,826	41,230	42,190	43,399	44,074	44,720

Fiscal years (HBIO's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(7,810)	(288)	(9,516)	(3,415)	(12,405)	(56,700)
Stock-based compensation	3,647	4,169	4,411	5,000	4,340	1,855
Net cash from operating activities	9,331	1,262	1,152	14,028	1,440	6,729
Purchases of property and equipment	1,152	1,195	1,590	1,788	2,644	1,258
Net cash from investing activities	(1,402)	(1,345)	(1,590)	(1,799)	(1,344)	(1,863)
Proceeds from long-term debt	—	—	—	—	0	40,000
Repayments of long-term debt	66,912	4,200	3,186	4,091	6,023	24,700
Net cash from financing activities	(7,967)	(252)	(2,837)	(12,134)	(131)	(1,291)
Net change in cash	(18)	(496)	(3,313)	(225)	(175)	4,506

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Harvard Bioscience	6,503	22,727	325*	4.6M	—	Q2 FY26 10-QJun 30, 2026
MultiSensor AI Holdings	21,005	1,695	(2,392)*	2.2M	8.8 quarters	Q2 FY26 10-QJun 30, 2026
Precipio	3,075	7,021	660*	1.8M	—	Q2 FY26 10-QJun 30, 2026
Focus Universal	1,600	675	(741)*	702,745	2.2 quarters	Q2 FY26 10-QJun 30, 2026
Optex Systems Holdings	6,175	9,729	2,323*	7.0M	—	Q3 FY26 10-QJun 28, 2026
Alamar Biosciences	121,532	33,545	(14,732)*	69.5M	13.3 quarters	Q3 FY26 10-QSep 30, 2026
Data I/O	10,843	5,149	(2,939)*	10.4M	3.7 quarters	Q2 FY26 10-QJun 30, 2026
Bionano Genomics	3,730	8,171	(4,670)*	11.8M	2.1 quarters	Q2 FY26 10-QJun 30, 2026
ClearSign Technologies	9,889	not reported	(1,236)*	6.8M	8.0 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.